Predictors of a Rapid Decline of Renal Function in Patients with Chronic Kidney Disease Referred to a Nephrology Outpatient Clinic: A Longitudinal Study
Table 3
Comparative analysis during the follow-up according to declining rates of renal function.
No rapid decline Annual loss ≤ 4 mL/min/1.73 m2
Rapid decline Annual loss > 4 mL/min/1.73 m2
value
HbA1c > 7% at any time during follow-up (%)
43 (20.8)
21 (33.3)
0.040
Incident CV event (%)
32 (15.5)
14 (22.2)
0.211
Acute myocardial infarction (%)
39 (19.0)
20 (30.8)
0.046
Stroke (%)
30 (14.6)
12 (18.5)
0.458
Congestive heart failure (%)
36 (17.6)
23 (35.4)
0.002
Lipid-lowering treatment (%)
103 (49.3)
35 (55.6)
0.600
Diuretic treatment, (%)
151 (72.9)
49 (77.8)
0.638
ACEI, (%)
90 (43.7)
26 (41.9)
0.807
ARB, (%)
68 (33)
18 (29)
0.556
CHB, (%)
65 (31.7)
23 (37.1)
0.084
BB, (%)
67 (32.8)
21 (33.3)
0.429
Serum uric acid (mg/dL)
7.3 ± 4.2
7.5 ± 1.5
0.743
Haemoglobin (g/dL)
13.2 ± 2.2
12.8 ± 1.6
0.183
Glucose (mg/dL)
116 ± 32
124 ± 44
0.118
Total cholesterol (mg/dL)
182 ± 36
178 ± 39
0.522
Serum triglycerides (mg/dL)
137 ± 97
142 ± 72
0.727
Proteinuria (g/24 h)
0.32 ± 0.58
0.80 ± 1.27
0.001
Serum albumin (g/dL)
4.2 ± 0.3
4.1 ± 0.3
0.008
Follow-up time, years
3.7 ± 2.3
2.2 ± 1.8
<0.001
CV: cardiovascular; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CHB: calcium channel blockers; BB: beta blocker. Data are presented as (%). Data are presented as the mean ± SD.
